Both organizations plan to contribute their respective areas of expertise to work on two research projects to improve patient treatment options and outcomes.
Based on genetic patterns in thousands of individuals with primary sclerosing cholangitis, researchers identified four new risk loci and explored ties to IBD.
The organizations in the consortium will identify, characterize, and catalog human biological molecules affected by physical activity in volunteer biosamples.
The study, which evaluated data from 65,000 women on 21 genes, identified new risk genes and those that confer no risk, and the findings may have clinical implications.
The company will still provide interpretation-only services, but by adding in-house testing it has dramatically increased its customer base.
Pittsburgh-based Curable is building a coalition to sequence genomes of patients with a rare autoimmune disease of the bile ducts to inform drug development.
Mayo will use Illumina's BaseSpace Clarity LIMS, BaseSpace Sequence Hub, and BaseSpace Variant Interpreter to annotate and interpret genetic variants.
After a boy's death, a family was wrongly diagnosed with Long QT syndrome following genetic testing, the Wall Street Journal reports.
At the Individualizing Medicine conference, researchers discussed cancer sequencing programs and strategies for increasing access to targeted therapies.
The research team's data demonstrated that Sanger confirmation is necessary to provide accurate NGS test results to patients.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.